Urology

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Urinary Bladder Neoplasms 96%
3. Urinary Bladder 91%
4. Prostatic Hyperplasia 87%
5. Prostate 81%
6. Kidney 73%
7. Neoplasms 67%
8. Nephrectomy 63%
9. Lower Urinary Tract Symptoms 63%
10. Renal Cell Carcinoma 59%
11. Carcinoma 57%
12. Cystectomy 51%
13. Stress Urinary Incontinence 43%
14. Recurrence 42%
15. Prostatectomy 41%
16. Nephroureterectomy 40%
17. Therapeutics 40%
18. Robotics 38%
19. Urodynamics 38%
20. Survival 35%
21. Urology 34%
22. Prostate-Specific Antigen 33%
23. Urinary Tract 26%
24. Dutasteride 26%
25. Radiofrequency Ablation 24%
26. Urologists 24%
27. Costs and Cost Analysis 22%
28. Urethral Stricture 22%
29. Artificial Urinary Sphincter 22%
30. Urine 21%
31. Laparoscopy 21%
32. Biopsy 21%
33. Pediatrics 21%
34. Vesico-Ureteral Reflux 20%
35. Urethra 20%
36. Cystoscopy 19%
37. Androgen Receptors 19%
38. Placebos 19%
39. Biomarkers 19%
40. Suburethral Slings 19%
41. Neoplasm Metastasis 18%
42. Drug Therapy 17%
43. Urinary Incontinence 17%
44. Androgens 17%
45. Child 17%
46. Pathologic Constriction 17%
47. Penile Prosthesis 17%
48. Nomograms 16%
49. Urinary Tract Infections 16%
50. Ureter 16%
51. Lymph Nodes 16%
52. Hydronephrosis 15%
53. Wounds and Injuries 15%
54. Quality of Life 15%
55. Finasteride 15%
56. Transitional Cell Carcinoma 15%
57. Surgeons 15%
58. Safety 15%
59. Lymph Node Excision 15%
60. Pressure 14%
61. Genes 14%
62. Tamsulosin 14%
63. Prolapse 14%
64. Swine 14%
65. Ureteroscopy 14%
66. Growth 13%
67. Urinary Retention 13%
68. Overactive Urinary Bladder 13%
69. Transurethral Resection of Prostate 13%
70. Kidney Calculi 13%
71. Guidelines 13%
72. Lithotripsy 12%
73. Urinary Bladder Neck Obstruction 12%
74. Erectile Dysfunction 12%
75. Equipment and Supplies 12%
76. Serum 12%
77. Urinary Diversion 12%
78. Morbidity 11%
79. Cell Biology 11%
80. Transplants 11%
81. Testis 11%
82. Proteins 11%
83. Testosterone 11%
84. Urolithiasis 11%
85. Pelvic Organ Prolapse 10%
86. Technology 10%
87. Tadalafil 10%
88. Incidence 10%
89. Operative Time 10%
90. Castration 10%
91. Population 10%
92. Radiotherapy 10%
93. Cost-Benefit Analysis 10%
94. Muscles 9%
95. Percutaneous Nephrolithotomy 9%
96. Hematuria 9%
97. Mortality 9%
98. Neurogenic Urinary Bladder 9%
99. Magnetic Resonance Imaging 9%
100. Hypospadias 9%